RESUMO
Malignant gastrointestinal neuroectodermal tumors (MGNETs), also known as "gastrointestinal clear cell sarcoma-like tumors", are very rare, aggressive sarcomas characterized by enteric location, distinctive pathologic features, and EWSR1/FUS::ATF1/CREB1 fusions. Despite identical genetics, the clinicopathologic features of MGNET are otherwise quite different from those of clear cell sarcoma of soft parts. Only exceptional extraenteric MGNET (E-MGNET) has been reported. We report a series of 11 E-MGNETs, the largest to date. Cases diagnosed with MGNET and occurring in nonintestinal locations were retrieved. A clinical follow-up was obtained. The tumors occurred in 3 men and 8 women (range, 14-70 years of age; median, 33 years) and involved the soft tissues of the neck (3), shoulder (1), buttock (2), orbit (1), tongue/parapharyngeal space (1), urinary bladder (1), and falciform ligament/liver (1). Tumors showed morphologic features of enteric MGNET (small, relatively uniform, round to ovoid cells with round, regular nuclei containing small nucleoli growing in multinodular and vaguely lobular patterns, with solid, pseudoalveolar, and pseudopapillary architecture). Immunohistochemical results were S100 protein (11/11), SOX10 (11/11), synaptophysin (3/10), CD56 (7/9), CD117 (3/9), DOG1 (0/4), ALK (4/8), chromogranin A (0/10), HMB-45 (0/11), Melan-A (0/11), tyrosinase (0/4), and MiTF (0/11). Next-generation sequencing results were EWSR1::ATF1 (7 cases), EWSR1::CREB1 (3 cases), and EWSR1::PBX1 (1 case). The EWSR1::PBX1-positive tumor was similar to other cases, including osteoclast-like giant cells, and negative for myoepithelial markers. A clinical follow-up (range, 10-70 months; median, 34 months) showed 4 patients dead of disease (10.5, 12, 25, and 64 months after diagnosis), 1 patient alive with extensive metastases (43 months after diagnosis), 1 patient alive with persistent local disease (11 months after diagnosis), and 4 alive without disease (10, 47, 53, and 70 months after diagnosis). One case is too recent for the follow-up. The clinicopathologic and molecular genetic features of rare E-MGNET are essentially identical to those occurring in intestinal locations. Otherwise, typical E-MGNET may harbor EWSR1::PBX1, a finding previously unreported in this tumor type. As in enteric locations, the behavior of E-MGNET is aggressive, with metastases and/or death from disease in at least 50% of patients. E-MGNET should be distinguished from clear cell sarcoma of soft parts and other tumors with similar fusions. ALK expression appears to be a common feature of tumors harboring EWSR1/FUS::ATF1/CREB1 fusion but is unlikely to predict the therapeutic response to ALK inhibition. Future advances in our understanding of these unusual tumors will hopefully lead to improved nomenclature.
Assuntos
Neoplasias Gastrointestinais , Tumores Neuroectodérmicos , Sarcoma de Células Claras , Masculino , Humanos , Feminino , Sarcoma de Células Claras/genética , Sarcoma de Células Claras/patologia , Hibridização in Situ Fluorescente , Neoplasias Gastrointestinais/genética , Neoplasias Gastrointestinais/patologia , Proteína EWS de Ligação a RNA/genética , Tumores Neuroectodérmicos/genética , Tumores Neuroectodérmicos/química , Tumores Neuroectodérmicos/patologia , Biologia Molecular , Receptores Proteína Tirosina Quinases/genética , Biomarcadores Tumorais/genética , Proteínas de Fusão Oncogênica/genéticaRESUMO
Malignant gastrointestinal neuroectodermal tumors (GNETs) are mesenchymal tumors that typically arise in the digestive tract and harbor EWSR1::ATF1 or EWSR1::CREB1 fusions. We report a case of primary retroperitoneal GNET in a 38-year-old woman who presented with a month-long fever with increased serum IL-6 level. A right retroperitoneal mass of 7 cm consisting of diffuse sheets of small cells with a high nuclear-to-cytoplasmic ratio and scattered osteoclast-like multinucleated giant cells was confirmed apart from the digestive tract. Peripheral lymphoid cuff and focal pseudoangiomatous spaces were present, reminiscent of angiomatoid fibrous histiocytoma. The tumor cells were positive for S100 protein and SOX10 and negative for melanocytic markers. Fluorescent in situ hybridization revealed EWSR1 and CREM gene rearrangements, consistent with EWSR1::CREM fusion, which has never been reported in GNET. The patient lives with recurrent lesions for 8 months. This case was associated with several unusual features and contributes to the evolving GNET concept.
Assuntos
Neoplasias Gastrointestinais , Tumores Neuroectodérmicos , Feminino , Humanos , Adulto , Interleucina-6/genética , Hibridização in Situ Fluorescente , Proteína EWS de Ligação a RNA/genética , Neoplasias Gastrointestinais/genética , Tumores Neuroectodérmicos/genética , Proteínas de Fusão Oncogênica/genética , Biomarcadores Tumorais/genética , Modulador de Elemento de Resposta do AMP Cíclico/genéticaRESUMO
Malignant gastrointestinal (GI) neuroectodermal tumor is an extremely rare entity that was first described by Zambrano et al. in 2003 as "clear cell sarcoma (CCS)-like tumor of the GI tract." It shares some of the histopathological features of CCS but lacks the immunohistochemical (IHC) reactivity for melanocytic markers. Most mesenchymal neoplasms of the GI tract belong to the category of GI stromal tumors and are characterized by the IHC expression of c-KIT. In cases, without detectable KIT receptor expression, several differential diagnoses have to be taken into consideration. In this article, we describe such a case and present a review of all the reported cases till date. We also present the current available knowledge on its pathology and molecular genetics along with the limitations in its diagnosis. Here, we report a case of a 32-year-old man with a tumor of the small bowel composed of polygonal tumor cells arranged in solid nests, alveolar pattern, and pseudopapillary and admixed with numerous osteoclast-like multinucleated giant cells. Immunohistochemically, the tumor cells strongly expressed S-100 protein only. HMB-45, melan-A, CD117, cytokeratin, desmin, smooth muscle actin, and CD-34 were absent. Ki-67 index was 15%. The diagnosis was further confirmed by fluorescence in situ hybridization (FISH) demonstrating the presence of EWSR1 (22q12) translocation. A final diagnosis of malignant gastroneuroectodermal tumor was rendered. The patient is disease-free for 20 months of postsurgery. The diagnosis of this entity should be considered in the presence of S-100-positivity and multinucleated osteoclastic giant cells and the absence of melanocytic differentiation in a tumor arising from GI tract. Further confirmation can be done by performing FISH analysis.
Assuntos
Neoplasias Gastrointestinais , Tumores Neuroectodérmicos , Sarcoma de Células Claras , Actinas/metabolismo , Biomarcadores Tumorais/metabolismo , Desmina/metabolismo , Neoplasias Gastrointestinais/diagnóstico , Neoplasias Gastrointestinais/genética , Neoplasias Gastrointestinais/patologia , Humanos , Hibridização in Situ Fluorescente , Queratinas , Antígeno Ki-67/metabolismo , Antígeno MART-1/metabolismo , Tumores Neuroectodérmicos/química , Tumores Neuroectodérmicos/diagnóstico , Tumores Neuroectodérmicos/genética , Proteínas S100/análise , Sarcoma de Células Claras/diagnóstico , Sarcoma de Células Claras/patologia , Sarcoma de Células Claras/cirurgiaRESUMO
Malignant gastrointestinal neuroectodermal tumour (GNET) is a rare, aggressive neoplasm with fewer than 100 cases reported in the literature. Most cases arise in the tubular gastrointestinal tract. We reported a unique case of GNET arising in the extrahepatic bile ducts and reviewed the literature of GNETs. The patient is a female in her mid-30s who presented with painless jaundice and diarrhoea several months after cholecystectomy for biliary dyskinesia. Workup revealed a tumour arising from the peripheral 4B bile ducts involving the left hepatic duct and bifurcation. Histologic examination of the lesion showed a malignant spindled and epithelioid neoplasm which strongly expressed S100 and SOX-10. Neoplastic cells were negative for various cytokeratins and melanoma markers. FISH testing using EWSR1 break-apart probes showed rearrangement of the EWSR1 gene region. The immunohistochemical and molecular findings are consistent with a diagnosis of GNET arising in the extrahepatic bile ducts.
Assuntos
Neoplasias dos Ductos Biliares , Ductos Biliares Extra-Hepáticos , Neoplasias Gastrointestinais , Tumores Neuroectodérmicos , Neoplasias dos Ductos Biliares/diagnóstico , Neoplasias dos Ductos Biliares/patologia , Neoplasias dos Ductos Biliares/cirurgia , Ductos Biliares Extra-Hepáticos/patologia , Colecistectomia , Feminino , Neoplasias Gastrointestinais/patologia , Humanos , Queratinas/análise , Tumores Neuroectodérmicos/genéticaRESUMO
Malignant gastrointestinal neuroectodermal tumor (GNET) is an ultra-rare soft tissue sarcoma, therefore often misdiagnosed and has no available standard treatment. Here, we report 3 cases of metastatic GNET with variable clinical courses. Our small case series as well as extensive literature review, further support that GNET is a spectrum of diseases with variable inherent biology and prognosis. Surgical management in the setting of recurrent/metastatic disease may be appropriate for GNET with indolent nature. Response to systemic treatments including chemotherapy and targeted treatments is variable, likely related to heterogenous biology as well. Furthermore, we retrospectively identified 20 additional GNET cases from Foundation Medicine's genomic database and expanded on their clinicopathological and genomic features. Comprehensive genomic profiling (CGP) with DNA and RNA sequencing of this cohort, in the course of clinical care, demonstrated recurrent EWSR1 chromosomal rearrangements and a sparsity of additional recurrent or driver genomic alterations. All cases had low tumor mutational burden (TMB) and were microsatellite stable.
Assuntos
Neoplasias Gastrointestinais , Tumores Neuroectodérmicos , Sarcoma de Células Claras , Neoplasias Gastrointestinais/genética , Genômica , Humanos , Tumores Neuroectodérmicos/diagnóstico , Tumores Neuroectodérmicos/genética , Tumores Neuroectodérmicos/patologia , Estudos Retrospectivos , Sarcoma de Células Claras/diagnóstico , Sarcoma de Células Claras/patologiaRESUMO
Malignant gastrointestinal neuroectodermal tumor (GNET) is a rare neoplasm with unknown etiology. It was previously referred to as Clear cell sarcoma of gastrointestinal tract. This tumor is characterized by a higher rate of local recurrence and metastasis. Due to its aggressive clinical course, distinguishing this entity from various other mimickers is very essential. Herein, we present a case of malignant GNET in a 33-year-old male patient.
Assuntos
Neoplasias Gastrointestinais/diagnóstico , Neoplasias Gastrointestinais/patologia , Trato Gastrointestinal/patologia , Tumores Neuroectodérmicos/diagnóstico , Tumores Neuroectodérmicos/patologia , Adulto , Biomarcadores Tumorais , Neoplasias Gastrointestinais/genética , Neoplasias Gastrointestinais/terapia , Humanos , Imuno-Histoquímica/métodos , Hibridização in Situ Fluorescente , Masculino , Tumores Neuroectodérmicos/genética , Tumores Neuroectodérmicos/terapia , Proteína EWS de Ligação a RNA/genética , Sarcoma de Células Claras/patologiaAssuntos
Neoplasias Gastrointestinais/patologia , Neoplasias Hepáticas/secundário , Neoplasias do Mediastino/tratamento farmacológico , Neoplasias do Mediastino/secundário , Tumores Neuroectodérmicos/patologia , Neoplasias Gastrointestinais/tratamento farmacológico , Neoplasias Gastrointestinais/genética , Neoplasias Gastrointestinais/cirurgia , Humanos , Neoplasias Hepáticas/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Tumores Neuroectodérmicos/tratamento farmacológico , Tumores Neuroectodérmicos/genética , Tumores Neuroectodérmicos/cirurgia , Proteína EWS de Ligação a RNA/genética , Resultado do TratamentoAssuntos
Regulação Neoplásica da Expressão Gênica/genética , Linfócitos do Interstício Tumoral , Paraganglioma , Feocromocitoma , Macrófagos Associados a Tumor , Neoplasias das Glândulas Suprarrenais/genética , Neoplasias das Glândulas Suprarrenais/imunologia , Neoplasias das Glândulas Suprarrenais/patologia , Algoritmos , Perfilação da Expressão Gênica/métodos , Mutação em Linhagem Germinativa , Humanos , Imunofenotipagem/métodos , Linfócitos do Interstício Tumoral/imunologia , Linfócitos do Interstício Tumoral/metabolismo , Aprendizado de Máquina , Proteínas dos Microfilamentos/genética , Tumores Neuroectodérmicos/genética , Tumores Neuroectodérmicos/imunologia , Tumores Neuroectodérmicos/patologia , Paraganglioma/genética , Paraganglioma/imunologia , Paraganglioma/patologia , Feocromocitoma/genética , Feocromocitoma/imunologia , Feocromocitoma/patologia , Proteínas Proto-Oncogênicas c-ret/genética , Proteínas de Ligação a RNA/genética , Análise de Sequência de RNA , Macrófagos Associados a Tumor/imunologia , Macrófagos Associados a Tumor/metabolismoRESUMO
Malignant gastrointestinal neuroectodermal tumor (M-GNET) and clear cell sarcoma (CCS) of soft tissue represent closely related, extremely rare, malignant mesenchymal neoplasm of uncertain differentiation. Both entities are characterized genetically by the same molecular alterations represented by the presence of EWSR1-ATF1 and, more rarely, EWSR1-CREB1 fusion genes. The latter translocation seems to be more represented in M-GNET that, despite significant morphologic overlap with CCS, tends to lack overt features of melanocytic differentiation. Most M-GNET occur in the lower gastrointestinal tract, whereas occurrence in the upper tract has been reported only exceptionally. The differential diagnosis represents a major challenge, and accurate diagnosis impact significantly on therapeutic planning. We herein report the clinicopathologic features of a molecularly confirmed M-GNET that arose at the base of the tongue and review the pertinent literature.
Assuntos
Biomarcadores Tumorais/metabolismo , Neoplasias Gastrointestinais/patologia , Tumores Neuroectodérmicos/patologia , Sarcoma de Células Claras/patologia , Proteínas de Ligação a Calmodulina/genética , Diagnóstico Diferencial , Feminino , Neoplasias Gastrointestinais/diagnóstico , Humanos , Pessoa de Meia-Idade , Tumores Neuroectodérmicos/diagnóstico , Tumores Neuroectodérmicos/genética , Sarcoma de Células Claras/diagnóstico , Sarcoma de Células Claras/genética , Translocação Genética/genéticaRESUMO
We report a case of a DICER1-associated EWSR1-rearranged malignant primitive neuroectodermal tumor (PNET) arising in a patient with DICER1 tumor predisposition syndrome. A 16-yr-old female with a history of multinodular goiter presented with a widely metastatic abdominal small round blue cell tumor with neuroectodermal differentiation. EWSR1 gene rearrangement was identified in the tumor by fluorescence in situ hybridization (FISH). Genetic analysis revealed biallelic pathogenic DICER1 variation. The patient was treated with an aggressive course of chemotherapy, surgery, and radiation with complete pathologic response. We believe this case to represent a new expression of the DICER1 tumor predisposition syndrome, an entity caused by deleterious germline mutations in the DICER1 gene, encoding a ribonuclease active in the processing of miRNA. Patients with germline mutations in DICER1 develop a diverse group of benign and malignant tumors. Some of these tumors have been noted to have immature neuroepithelium as a component, including the ciliary body medulloepithelioma and the recently described DICER1-associated presacral malignant teratoid neoplasm. To our knowledge, abdominal sarcomas that resemble PNET histology with an EWSR1 rearrangement have not previously been described as a classical expression of the DICER1 syndrome phenotype.
Assuntos
Tumores Neuroectodérmicos/genética , Proteína EWS de Ligação a RNA/genética , Adolescente , RNA Helicases DEAD-box/metabolismo , Feminino , Rearranjo Gênico/genética , Mutação em Linhagem Germinativa , Humanos , Hibridização in Situ Fluorescente , Metástase Neoplásica/genética , Tumores Neuroectodérmicos/metabolismo , Proteína EWS de Ligação a RNA/metabolismo , Ribonuclease III/metabolismo , Sarcoma de Ewing/genética , Sarcoma de Ewing/metabolismoRESUMO
Disparities in cancer patient responses have prompted widespread searches to identify differences in sensitive vs. nonsensitive populations and form the basis of personalized medicine. This customized approach is dependent upon the development of pathway-specific therapeutics in conjunction with biomarkers that predict patient responses. Here, we show that Cdk5 drives growth in subgroups of patients with multiple types of neuroendocrine neoplasms. Phosphoproteomics and high throughput screening identified phosphorylation sites downstream of Cdk5. These phosphorylation events serve as biomarkers and effectively pinpoint Cdk5-driven tumors. Toward achieving targeted therapy, we demonstrate that mouse models of neuroendocrine cancer are responsive to selective Cdk5 inhibitors and biomimetic nanoparticles are effective vehicles for enhanced tumor targeting and reduction of drug toxicity. Finally, we show that biomarkers of Cdk5-dependent tumors effectively predict response to anti-Cdk5 therapy in patient-derived xenografts. Thus, a phosphoprotein-based diagnostic assay combined with Cdk5-targeted therapy is a rational treatment approach for neuroendocrine malignancies.
Assuntos
Neoplasias/tratamento farmacológico , Neoplasias/metabolismo , Tumores Neuroectodérmicos/tratamento farmacológico , Fosfoproteínas/metabolismo , Inibidores de Proteínas Quinases/administração & dosagem , Animais , Biomarcadores/análise , Biomarcadores/metabolismo , Quinase 5 Dependente de Ciclina/antagonistas & inibidores , Quinase 5 Dependente de Ciclina/genética , Quinase 5 Dependente de Ciclina/metabolismo , Xenoenxertos , Humanos , Camundongos , Neoplasias/genética , Tumores Neuroectodérmicos/genética , Tumores Neuroectodérmicos/metabolismo , Fosfoproteínas/análise , Fosfoproteínas/genética , FosforilaçãoRESUMO
A malignant gastrointestinal neuroectodermal tumor (GNET) is rare, and it is therefore yet to be completely understood. This study aimed to present the clinicopathologic features of GNET, including treatment information. We included 19 patients with GNET with a mean tumor size of 4.2 cm. The most common site of tumor origin was the small intestine (57.9%), followed by the stomach (15.8%), colon (10.5%), ileocecal junction (5.3%), lower esophagus (5.3%), and anal canal (5.3%). Microscopically, the tumors were composed of epithelioid cells with eosinophilic or clear cytoplasm arranged in nest, sheet-like, papillary, or pseudoalveolar patterns and/or spindle tumor cells with eosinophilic cytoplasm arranged in a fascicular pattern. Immunohistochemically, the tumor cells stained positively for S100 (19/19,100%), SOX10 (14/15, 93.3%), vimentin (17/17, 100%), synaptophysin (Syn) (7/17, 41.2%), CD56 (4/13, 30.8%), CD99 (1/5, 20%), and CD117 (1/15, 6.7%), and negatively for HMB45, Melan A, DOG1, CD34, AE1/AE3, CAM5.2, chromogranin A, smooth muscle actin, and desmin. In total, 14/15 (93.3%) cases showed split Ewing sarcoma breakpoint region 1 gene (EWSR1) signals consistent with a chromosomal translocation involving EWSR1. Within a mean follow-up of 29.7 months (range: 3 to 63 mo), 2/15 (13.3%) patients died of disease, 5 (33.3%) were alive with disease, and 8 (53.3%) had no evidence of disease. Two and 1 patients showed partial response to apatinib and anlotinib, respectively. In conclusion, GNET has distinctive morphologic, immunohistochemical, and molecular genetic features and should be distinguished from other gastrointestinal tract malignancies. Apatinib and anlotinib might be effective for the treatment of advanced GNET and could prolong patient survival.
Assuntos
Biomarcadores Tumorais , Neoplasias Gastrointestinais , Imuno-Histoquímica , Hibridização in Situ Fluorescente , Tumores Neuroectodérmicos , Proteína EWS de Ligação a RNA/genética , Translocação Genética , Adulto , Antineoplásicos/uso terapêutico , Biomarcadores Tumorais/análise , Biomarcadores Tumorais/genética , Feminino , Neoplasias Gastrointestinais/química , Neoplasias Gastrointestinais/tratamento farmacológico , Neoplasias Gastrointestinais/genética , Neoplasias Gastrointestinais/patologia , Predisposição Genética para Doença , Humanos , Indóis/uso terapêutico , Masculino , Pessoa de Meia-Idade , Tumores Neuroectodérmicos/química , Tumores Neuroectodérmicos/tratamento farmacológico , Tumores Neuroectodérmicos/genética , Tumores Neuroectodérmicos/patologia , Valor Preditivo dos Testes , Inibidores de Proteínas Quinases/uso terapêutico , Piridinas/uso terapêutico , Quinolinas/uso terapêutico , Resultado do Tratamento , Carga TumoralRESUMO
Malignant gastrointestinal neuroectodermal tumour (GNET) is a recently characterised rare and aggressive tumour that typically arises in association with the small intestine of adults. We present a novel case of this entity and expand the spectrum of its reported morphological features. The patient was a 5-year-old female, the youngest reported patient affected by the condition, and presented with extra-abdominal disease. The histopathological features included the presence of a junctional component of the palatal tumour, which mimicked mucosal melanoma, a feature that has not been previously reported in GNET. Whole genome and RNA sequencing was performed that demonstrated the EWSR1-ATF1 translocation characteristic of GNET. Knowledge of this entity and its features, together with careful morphological assessment supplemented by judicious immunohistochemical and molecular studies should enable the correct diagnosis to be established.
Assuntos
Tumores Neuroectodérmicos/patologia , Neoplasias Parotídeas/genética , Neoplasias Parotídeas/patologia , Fatores de Transcrição/genética , Pré-Escolar , Diagnóstico Diferencial , Feminino , Mutação em Linhagem Germinativa , Humanos , Melanoma/diagnóstico , Melanoma/patologia , Tumores Neuroectodérmicos/diagnóstico , Tumores Neuroectodérmicos/genética , Neoplasias Parotídeas/diagnóstico , LinhagemRESUMO
Clear cell sarcoma is an uncommon sarcoma which rarely occurs as a primary tumour in the gastrointestinal tract (CCS-GIT). It shares common molecular genetic abnormalities with the more recently described entity, malignant gastrointestinal neuroectodermal tumour (GNET) but is distinguished by its morphological and immunohistochemical findings. The exact nosological relationship between these tumours continues to be debated. In this review, we present two cases of these rare neoplasms from our files and perform a statistical comparison of all published cases to determine if significant differences exist in their clinicopathological features and biological behaviour. Thirteen cases of CCS-GIT and 58 of GNET were included. CCS-GIT occurred more commonly in males (84.6% vs 46.6%, p = 0.01) and in an older age group (median 57 vs 33 years, p < 0.01). There was no significant difference in their location in the gastrointestinal tract, median tumour size and proportion of cases with an EWSR1-ATF1 vs EWSR1-CREB1 fusion. Median survival for CCS-GIT was 13.5 months and for GNET, 9.5 months (p = 0.78). There was no significant difference in the Kaplan-Meier survival curves for either time to first metastasis (p = 0.88) or overall survival (p = 0.18), including after controlling for tumour size using regression models. Our analysis confirms that aside from morphological variations between these tumours, they also exhibit epidemiological and clinical differences. Despite the prevalent perception that GNET is associated with a more aggressive clinical course, our findings indicate that there is no significant difference in their biological behaviour, although both clearly share a bleak prognosis. Further experience is awaited to determine optimal treatment strategies and whether CCS-GIT and GNET would differ in their response to various therapies.
Assuntos
Proteínas de Ligação a Calmodulina/genética , Neoplasias Gastrointestinais/genética , Trato Gastrointestinal/patologia , Tumores Neuroectodérmicos/genética , Sarcoma de Células Claras/patologia , Biomarcadores Tumorais/análise , Neoplasias Gastrointestinais/patologia , Humanos , Tumores Neuroectodérmicos/patologiaRESUMO
We present a case of a 14-year-old girl who was diagnosed with Burkitt lymphoma in 2014. She was managed with chemotherapy and remained in remission for 3 years. On her surveillance imaging in 2017, a left-sided renal neoplastic mass was incidentally discovered. She underwent nephrectomy and pathology of the resected specimen revealed small cell tumour of the kidney with features favouring renal Ewing sarcoma/primitive neuroectodermal tumour. Molecular genetic analysis by fluorescence in situ hybridisation was performed which showed translocation of 22q12, thereby confirming the diagnosis. This is a rare secondary malignancy and an unusual association. This case highlights the importance and diagnostic dilemmas of rare secondary tumours in patients with such haematological malignancies and discusses its possible pathogenetic aspects.
Assuntos
Neoplasias Renais/diagnóstico , Tumores Neuroectodérmicos/diagnóstico , Sarcoma de Ewing/diagnóstico , Adolescente , Linfoma de Burkitt/tratamento farmacológico , Feminino , Humanos , Neoplasias Renais/genética , Segunda Neoplasia Primária/etiologia , Segunda Neoplasia Primária/genética , Nefroureterectomia , Tumores Neuroectodérmicos/genética , Sarcoma de Ewing/genéticaRESUMO
PURPOSE OF REVIEW: Brain tumors are the most common solid tumors and leading cause of cancer-related death in children. The advent of large-scale genomics has resulted in a plethora of profiling studies that have mapped the genetic and epigenetic landscapes of pediatric brain tumors, ringing in a new era of precision diagnostics and targeted therapies. In this review, we highlight the most recent findings, focusing on studies published after 2015, and discuss how new evidence is changing the care of children with brain tumors. RECENT FINDINGS: Genome-wide and epigenome-wide profiling data have revealed distinct tumor entities within, virtually, all pediatric brain tumor groups including medulloblastoma; ependymoma; high-grade and low-grade gliomas; atypical teratoid/rhabdoid tumors; and other embryonal tumors, previously called CNS primitive neuroectodermal tumors. Whenever integrated with clinical information, many molecular alterations emerge as powerful prognostic markers and should thus be used to stratify patients and tailor therapies. SUMMARY: Optimal integration of this newly emerging knowledge in a timely and meaningful way into clinical care is a remarkable task and a matter of active debate. The historical morphology-based classification of tumors is being replaced by a genetic-based classification, and the first generation of molecularly informed clinical trials is underway.
Assuntos
Neoplasias Encefálicas/genética , Neoplasias Encefálicas/terapia , Biomarcadores Tumorais/genética , Neoplasias Encefálicas/classificação , Neoplasias Encefálicas/diagnóstico , Criança , Epigênese Genética , Predisposição Genética para Doença , Testes Genéticos , Estudo de Associação Genômica Ampla , Genômica , Humanos , Tumores Neuroectodérmicos/classificação , Tumores Neuroectodérmicos/diagnóstico , Tumores Neuroectodérmicos/genética , Tumores Neuroectodérmicos/terapia , Pediatria , Medicina de Precisão , Tumor Rabdoide/classificação , Tumor Rabdoide/diagnóstico , Tumor Rabdoide/genética , Tumor Rabdoide/terapia , Teratoma/classificação , Teratoma/diagnóstico , Teratoma/genética , Teratoma/terapiaRESUMO
AIMS: Malignant ectomesenchymoma is a rare pediatric neoplasm with dual mesenchymal and neuroectodermal elements. Mesenchymal component is usually rhabdomyosarcoma, particularly embryonal subtype, whereas neuroectodermal derivatives are frequently a neuroblastic tumor. Ectomesenchymoma manifests in various sites given the wide migration of neural crest cells during development, though the pelvis/perineum is most often involved. Moreover, no unique unifying molecular abnormality has been determined. METHODS: We conducted a retrospective study to analyze the spectrum of ectomesenchymal tumors encountered in our pediatric population. Six patients were identified and data pertaining to patients' demographic, tumor size and site, histologic components with immunophenotypic profile, molecular alterations, treatment, and outcome were collected. RESULTS: Mesenchymal elements, represented by rhabdomyosarcoma in all instances, were the dominant component in the majority of cases (5/6). Embryonal and alveolar morphology had similar distribution (3/6) and all patients with alveolar subtype harbored the characteristic translocations of this entity. The neuroectodermal component was most often a neuroblastic-like neoplasm (4/6); however, 2/6 cases demonstrated primitive neuroectodermal tumor-like morphology. No unifying alterations were found on molecular studies. CONCLUSIONS: Our analysis extends the histologic and molecular spectrum of these tumors and highlights their heterogeneity. The percentage of cases with alveolar rhabdomyosarcoma or primitive neuroectodermal-like tumor components suggests that these types of elements might be underreported. This study is also the first to demonstrate FOXO1 gene rearrangements in malignant ectomesenchymoma with alveolar rhabdomyosarcoma subtype.
Assuntos
Tumores Neuroectodérmicos/patologia , Rabdomiossarcoma/patologia , Adolescente , Pré-Escolar , Feminino , Proteína Forkhead Box O1/genética , Rearranjo Gênico , Humanos , Lactente , Recém-Nascido , Masculino , Tumores Neuroectodérmicos/genética , Estudos Retrospectivos , Rabdomiossarcoma/genéticaRESUMO
BACKGROUND: Malignant gastrointestinal neuroectodermal tumor (GNET) is an extremely rare entity that was first described by Zambrano et al. in 2003 as "Clear cell sarcoma-like tumor of the gastrointestinal tract". It shares some of the histological features of clear cell sarcoma (CCS) but lacks the immunohistochemical reactivity for melanocytic markers. We report a case of GNET that was initially misdiagnosed as gastrointestinal stromal tumor (GIST). Recognizing this entity is important to avoid misdiagnosis. CASE PRESENTATION: A case of an 18-year-old male presented with a small intestinal tumor. Histologically it was characterized by polygonal cells arranged in pseudoalveolar pattern and situated in the muscularis propria. Scattered osteoclast-like multinucleated giant cells were also noted. The neoplastic cells were positive for S-100 protein and negative for HMB-45, Melan A, smooth muscle actin, desmin and CD117. EWSR1 gene rearrangement was detected by fluorescence in situ hybridization (FISH) analysis. The patient returned with recurrence after 36 months' management by surgical resection and died one year later. CONCLUSIONS: GNET can be mistaken histologically for other non-epithelial gastrointestinal tumors. Awareness of its existence and diagnostic criteria by the pathologist is necessary to avoid misdiagnosis, particularly as GIST, CCS or malignant peripheral nerve sheath tumor (MPNST).
Assuntos
Tumores do Estroma Gastrointestinal/patologia , Neoplasias do Jejuno/patologia , Tumores Neuroectodérmicos/patologia , Adolescente , Biomarcadores Tumorais/análise , Biomarcadores Tumorais/genética , Biópsia , Proteínas de Ligação a Calmodulina/genética , Erros de Diagnóstico , Evolução Fatal , Tumores do Estroma Gastrointestinal/química , Tumores do Estroma Gastrointestinal/genética , Rearranjo Gênico , Humanos , Imuno-Histoquímica , Hibridização in Situ Fluorescente , Neoplasias do Jejuno/química , Neoplasias do Jejuno/genética , Neoplasias do Jejuno/cirurgia , Masculino , Recidiva Local de Neoplasia , Tumores Neuroectodérmicos/química , Tumores Neuroectodérmicos/genética , Tumores Neuroectodérmicos/cirurgia , Valor Preditivo dos Testes , Proteína EWS de Ligação a RNA , Proteínas de Ligação a RNA/genética , Fatores de Tempo , Resultado do TratamentoRESUMO
Malignant gastrointestinal neuroectodermal tumor (GNET) is an aggressive rare tumor, primarily occurring in young adults with frequent local-regional metastases and recurrence after local control. The tumor is characterized by the presence of EWSR1-ATF1 or EWSR1-CREB1 and immunohistochemical positivity for S-100 protein without melanocytic marker positivity. Due to poor responses to standard sarcoma regimens, GNET has a poor prognosis, and development of effective systemic therapy is desperately needed to treat these patients. Herein, we present a patient with a small bowel GNET who experienced recurrent hepatic and skeletal metastases after a primary resection. Comprehensive genomic profiling (CGP) in the course of clinical care with DNA and RNA sequencing demonstrated the presence of an exon 7 to exon 6 EWSR1-CREB1 fusion in the context of a diploid genome with no other genomic alterations. In a clinical trial, the patient received a combination of 250 mg crizotinib with 600 mg pazopanib quaque die and achieved partial response and durable clinical benefit for over 2.8 years, and with minimal toxicity from therapy. Using a CGP database of over 50,000 samples, we identified 11 additional cases that harbor EWSR1-CREB1 and report clinicopathologic characteristics, as these patients may also benefit from such a regimen.